Scienture Gains 180-Day Reprieve from Nasdaq to Avoid Delisting
Event summary
- Scienture received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, extending the deadline to October 12, 2026.
- The company's stock will continue trading on the Nasdaq Capital Market under the symbol SCNX.
- Scienture highlights momentum in its commercial portfolio, including the launch of Arbli™ for hypertension and the upcoming launch of REZENOPY™ for opioid overdose treatment.
- Arbli™ is the first FDA-approved liquid formulation of losartan, addressing unmet needs in hypertension treatment.
The big picture
Scienture's extension from Nasdaq reflects broader challenges faced by small-cap pharmaceutical companies in maintaining compliance with listing requirements. The company's focus on novel specialty products like Arbli™ and REZENOPY™ aligns with industry trends toward addressing unmet medical needs, particularly in hypertension and opioid overdose treatment. The strategic priority lies in balancing regulatory compliance with commercial execution to ensure long-term growth.
What we're watching
- Compliance Risk
- Whether Scienture can sustain its stock price above $1.00 for ten consecutive business days within the 180-day extension period.
- Revenue Growth
- The pace at which Arbli™ and REZENOPY™ drive revenue growth into 2026 and beyond.
- Product Execution
- How Scienture's scalable commercial infrastructure supports the launch and market penetration of REZENOPY™ in Q2 2026.
Related topics